Full dose rivaroxaban

Phase 3Small molecule

OOttawa Hospital Research Institute

Full dose rivaroxaban is one of 3 small molecule programs targeting Rivaroxaban. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RivaroxabanRecruiting

RivaroxabanPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Rivaroxaban

#DrugCompanyPhaseTrials

Xarelto

WWim Janssens

Approved

62 2

Rivoroxaban

FFoundation University Islamabad

Phase 3

1 3

Full dose rivaroxaban

OOttawa Hospital Research Institute

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Recruiting

Rivaroxaban

NCT06965998

Clinical

Trials by Indication[1]

Rivaroxaban1 trial

A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg

Recruiting·OOttawa Hospital Research Institute·Phase 2/3·NCT06965998·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Full dose rivaroxaban. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Full dose rivaroxaban compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Full dose rivaroxaban. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ottawa Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOttawa Hospital Research Institute

Full dose rivaroxaban

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Rivaroxaban1 trial

References

Drug Info

Quick Facts

Related News